These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

585 related articles for article (PubMed ID: 16984552)

  • 1. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
    Okegawa T; Kinjo M; Nutahara K; Higashihara E
    Int J Urol; 2006 Sep; 13(9):1197-201. PubMed ID: 16984552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of serum HER2/neu with immunohistochemical HER2/neu expression for the prediction of biochemical progression in metastatic prostate cancer.
    Tambo M; Higashihara E; Terado Y; Nutahara K; Okegawa T
    Int J Urol; 2009 Apr; 16(4):369-74. PubMed ID: 19207111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
    Soga N; Onishi T; Arima K; Sugimura Y
    Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
    Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
    BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort.
    Tahir SA; Frolov A; Hayes TG; Mims MP; Miles BJ; Lerner SP; Wheeler TM; Ayala G; Thompson TC; Kadmon D
    Clin Cancer Res; 2006 Aug; 12(16):4872-5. PubMed ID: 16914574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
    Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
    Janoff DM; Peterson C; Mongoue-Tchokote S; Peters L; Beer TM; Wersinger EM; Mori M; Garzotto M
    BJU Int; 2005 Sep; 96(4):503-7. PubMed ID: 16104900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAG polymorphic repeat length in androgen receptor gene combined with pretreatment serum testosterone level as prognostic factor in patients with metastatic prostate cancer.
    Shimbo M; Suzuki H; Kamiya N; Imamoto T; Komiya A; Ueda T; Watanabe M; Shiraishi T; Ichikawa T
    Eur Urol; 2005 Apr; 47(4):557-63. PubMed ID: 15774258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
    Magheli A; Rais-Bahrami S; Carter HB; Peck HJ; Epstein JI; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1277-80; discussion 1280-1. PubMed ID: 17698121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic factors of prostate cancer treated with first-line hormone therapy].
    Rigaud J; Le Normand L; Karam G; Glemain P; Buzelin JM; Bouchot O
    Prog Urol; 2002 Apr; 12(2):232-9. PubMed ID: 12108337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients.
    Sasaki T; Komiya A; Suzuki H; Shimbo M; Ueda T; Akakura K; Ichikawa T
    Eur Urol; 2005 Aug; 48(2):224-9; discussion 229-30. PubMed ID: 16005374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy.
    Massengill JC; Sun L; Moul JW; Wu H; McLeod DG; Amling C; Lance R; Foley J; Sexton W; Kusuda L; Chung A; Soderdahl D; Donahue T
    J Urol; 2003 May; 169(5):1670-5. PubMed ID: 12686805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer.
    Shariat SF; Bensalah K; Karam JA; Roehrborn CG; Gallina A; Lotan Y; Slawin KM; Karakiewicz PI
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5377-84. PubMed ID: 17875766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival.
    Cheville JC; Tindall D; Boelter C; Jenkins R; Lohse CM; Pankratz VS; Sebo TJ; Davis B; Blute ML
    Cancer; 2002 Sep; 95(5):1028-36. PubMed ID: 12209687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of shed Her2/neu protein in men with prostate cancer correlate with disease progression.
    Osman I; Mikhail M; Shuch B; Clute M; Cheli CD; Ghani F; Thiel RP; Taneja SS
    J Urol; 2005 Dec; 174(6):2174-7. PubMed ID: 16280758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretherapeutic erythrocyte polyamine spermine levels discriminate high risk relapsing patients with M1 prostate carcinoma.
    Cipolla BG; Ziade J; Bansard JY; Moulinoux JP; Staerman F; Quemener V; Lobel B; Guillé F
    Cancer; 1996 Sep; 78(5):1055-65. PubMed ID: 8780544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
    Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
    Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.